Literature DB >> 19828640

PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.

Shruti Desai1, Sophia C E Bolick, Michelle Maurin, Kenneth L Wright.   

Abstract

The human positive regulatory domain I-binding factor 1 (PRDI-BF1) and its murine homolog Blimp-1 promote differentiation of mature B cells into Ab-secreting plasma cells. In contrast, ectopic expression of PRDI-BF1 in lymphoma cells can lead to inhibition of proliferation or apoptosis. However, little is currently known about the regulation of PRDM1, the gene encoding PRDI-BF1. This report establishes that in lymphoma cells stimulation through the BCR rapidly induces endogenous PRDM1 at the level of transcription with minor changes in mRNA stability. The induced PRDM1-encoded protein localizes to its target genes in vivo and suppresses their expression. In vivo genomic footprinting of the PRDM1 promoter in unstimulated lymphoma and myeloma cells reveals multiple common in vivo occupied elements throughout the promoter. Further functional and structural analysis of the promoter reveals that the promoter is preloaded and poised for activation in the B cell lines. The transcription factor PU.1 is shown to be required for the BCR-induced expression of PRDM1 in lymphoma cells and in PU.1-positive myeloma cells. Activation of PRDM1 is associated with loss of the corepressor transducin-like enhancer of split 4 from the PU.1 complex. These findings indicate that PRDM1 is poised for activation in lymphoma cells and therefore may be a potential therapeutic target to inhibit lymphoma cell proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828640      PMCID: PMC3164282          DOI: 10.4049/jimmunol.0901120

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.

Authors:  N Ghosh; I Gyory; G Wright; J Wood; K L Wright
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

2.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.

Authors:  A L Shaffer; Kuo I Lin; Tracy C Kuo; Xin Yu; Elaine M Hurt; Andreas Rosenwald; Jena M Giltnane; Liming Yang; Hong Zhao; Kathryn Calame; Louis M Staudt
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

3.  BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.

Authors:  J F Piskurich; K I Lin; Y Lin; Y Wang; J P Ting; K Calame
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

4.  A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes.

Authors:  N Ghosh; J F Piskurich; G Wright; K Hassani; J P Ting; K L Wright
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.

Authors:  G B Carey; D W Scott
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  Displacement of an E-box-binding repressor by basic helix-loop-helix proteins: implications for B-cell specificity of the immunoglobulin heavy-chain enhancer.

Authors:  T Genetta; D Ruezinsky; T Kadesch
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

7.  Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma.

Authors:  Nancy D Borson; Martha Q Lacy; Peter J Wettstein
Journal:  Blood       Date:  2002-12-15       Impact factor: 22.113

8.  Characterization of the B lymphocyte-induced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter.

Authors:  C Tunyaplin; M A Shapiro; K L Calame
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

9.  Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.

Authors:  Farha H Vasanwala; Saritha Kusam; Lisa M Toney; Alexander L Dent
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

10.  Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.

Authors:  Kuo-I Lin; Cristina Angelin-Duclos; Tracy C Kuo; Kathryn Calame
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

View more
  12 in total

1.  PRDM1 is required for mantle cell lymphoma response to bortezomib.

Authors:  Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.

Authors:  Elena Cubedo; Michelle Maurin; Xiaoyu Jiang; Izidore S Lossos; Kenneth L Wright
Journal:  FEBS J       Date:  2011-08-02       Impact factor: 5.542

3.  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

Authors:  David M Woods; Andressa L Sodré; Alejandro Villagra; Amod Sarnaik; Eduardo M Sotomayor; Jeffrey Weber
Journal:  Cancer Immunol Res       Date:  2015-08-21       Impact factor: 11.151

4.  PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

Authors:  N Ueno; N Nishimura; S Ueno; S Endo; H Tatetsu; S Hirata; H Hata; M Matsuoka; H Mitsuya; Y Okuno
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

5.  Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.

Authors:  Kui Nie; Taotao Zhang; Hatim Allawi; Mario Gomez; Yifang Liu; Amy Chadburn; Y Lynn Wang; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

6.  PRDM1/Blimp-1 controls effector cytokine production in human NK cells.

Authors:  Matthew A Smith; Michelle Maurin; Hyun Il Cho; Brian Becknell; Aharon G Freud; Jianhua Yu; Sheng Wei; Julie Djeu; Esteban Celis; Michael A Caligiuri; Kenneth L Wright
Journal:  J Immunol       Date:  2010-10-13       Impact factor: 5.422

7.  Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Mol Immunol       Date:  2017-08-31       Impact factor: 4.407

8.  Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential.

Authors:  B De Craene; G Denecker; P Vermassen; J Taminau; C Mauch; A Derore; J Jonkers; E Fuchs; G Berx
Journal:  Cell Death Differ       Date:  2013-10-25       Impact factor: 15.828

9.  Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.

Authors:  Ziyang Yu; Seiichi Sato; Philip C Trackman; Kathrin H Kirsch; Gail E Sonenshein
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

10.  SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.

Authors:  Matthew A Care; Mario Cocco; Jon P Laye; Nicholas Barnes; Yuanxue Huang; Ming Wang; Sharon Barrans; Ming Du; Andrew Jack; David R Westhead; Gina M Doody; Reuben M Tooze
Journal:  Nucleic Acids Res       Date:  2014-05-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.